{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:12:52Z","timestamp":1794809572407,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pfizer, Inc."},{"name":"Arvinas Estrogen Receptor, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vepdegestrant (ARV-471) is an oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase 1 study (NCT05463952) investigated safety, pharmacokinetics, and antitumor activity of vepdegestrant in Japanese patients with ER-positive (ER+)\/human epidermal growth factor receptor 2\u2013negative (HER2-) advanced breast cancer at the 200-mg once daily (QD) recommended phase 3 dose. Eligible patients had ER+\/HER2- advanced breast cancer resistant to standard therapy, with no standard therapy available, or had received two or more prior endocrine therapies in any setting. The primary endpoint was dose-limiting toxicities (DLTs) in cycle 1; secondary endpoints included safety, pharmacokinetics, and antitumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six female patients (median age, 58 [range: 47\u201362] years) were treated. For advanced disease, three (50.0%) patients received three or more prior regimens and five (83.3%) patients received prior cyclin-dependent kinase 4\/6 inhibitors. At data cutoff, median treatment duration was 9.8 (range: 6\u201328) weeks; two patients remained on treatment. No DLTs were observed. Four (66.7%) patients experienced adverse events; none led to dose reduction or discontinuation. Four (66.7%) patients had treatment-related adverse events; all were grade 1 except anemia (grade 2). Geometric mean maximum plasma concentration and 24-h area under the plasma concentration\u2013time curve of vepdegestrant were 630.9\u202fng\/mL and 10,400\u202fng\u2219hr\/mL after a single dose and 1056\u202fng\/mL and 18,310\u202fng\u2219hr\/mL after multiple doses. Two (33.3%) patients demonstrated stable disease at week 24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vepdegestrant 200 mg QD was well tolerated in Japanese patients with ER+\/HER2- advanced breast cancer with no notable differences in pharmacokinetics from Western patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov: NCT05463952 (date of registration: July 19, 2022).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-024-02648-3","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T07:32:09Z","timestamp":1732087929000},"page":"72-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+\u2009advanced breast cancer: a phase 1 study"],"prefix":"10.1007","volume":"30","clinical-trial-number":[{"clinical-trial-number":"nct05463952","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Hiroji","family":"Iwata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyo","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mana","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Umeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Mukohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2648_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"2648_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3322\/caac.21754","volume":"72","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto AN, Sung H, Miller KD et al (2022) Breast cancer statistics, 2022. CA Cancer J Clin 72:524\u2013541. https:\/\/doi.org\/10.3322\/caac.21754","journal-title":"CA Cancer J Clin"},{"key":"2648_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert LA, Gumusay O, Idossa D et al (2023) Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin 73:480\u2013515. https:\/\/doi.org\/10.3322\/caac.21777","journal-title":"CA Cancer J Clin"},{"key":"2648_CR4","unstructured":"Cancer stat facts: female breast cancer subtypes. National Cancer Institute: Surveillance, Epidemology, and End Results Program. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html. Accessed 16 Apr 2024"},{"key":"2648_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12282-022-01423-4","volume":"30","author":"K Tada","year":"2023","unstructured":"Tada K, Kumamaru H, Miyata H et al (2023) Characteristics of female breast cancer in Japan: annual report of the National Clinical Database in 2018. Breast Cancer 30:157\u2013166. https:\/\/doi.org\/10.1007\/s12282-022-01423-4","journal-title":"Breast Cancer"},{"key":"2648_CR6","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/jco.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Somerfield MR, Barton DL et al (2021) Endocrine treatment and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative metastatic breast cancer: ASCO guideline update. J Clin Oncol 39:3959\u20133977. https:\/\/doi.org\/10.1200\/jco.21.01392","journal-title":"J Clin Oncol"},{"key":"2648_CR7","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH et al (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32:1475\u20131495. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"key":"2648_CR8","doi-asserted-by":"publisher","first-page":"175883592211136","DOI":"10.1177\/17588359221113694","volume":"14","author":"MR Lloyd","year":"2022","unstructured":"Lloyd MR, Wander SA, Hamilton E et al (2022) Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther Adv Med Oncol 14:17588359221113694. https:\/\/doi.org\/10.1177\/17588359221113694","journal-title":"Ther Adv Med Oncol"},{"key":"2648_CR9","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2159-8290.Cd-19-1390","volume":"10","author":"SA Wander","year":"2020","unstructured":"Wander SA, Cohen O, Gong X et al (2020) The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptorpositive metastatic breast cancer. Cancer Discov 10:1174\u20131193. https:\/\/doi.org\/10.1158\/2159-8290.Cd-19-1390","journal-title":"Cancer Discov"},{"key":"2648_CR10","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623\u20131649. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010","journal-title":"Ann Oncol"},{"key":"2648_CR11","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299\u20131309. https:\/\/doi.org\/10.1093\/jnci\/djr242","journal-title":"J Natl Cancer Inst"},{"key":"2648_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","volume":"37","author":"AB Hanker","year":"2020","unstructured":"Hanker AB, Sudhan DR, Arteaga CL (2020) Overcoming endocrine resistance in breast cancer. Cancer Cell 37:496\u2013513. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.009","journal-title":"Cancer Cell"},{"key":"2648_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.cell.2019.06.026","volume":"178","author":"J Guan","year":"2019","unstructured":"Guan J, Zhou W, Hafner M et al (2019) Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell 178:949-963.e918. https:\/\/doi.org\/10.1016\/j.cell.2019.06.026","journal-title":"Cell"},{"key":"2648_CR14","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10549-011-1947-7","volume":"133","author":"I Kuter","year":"2012","unstructured":"Kuter I, Gee JM, Hegg R et al (2012) Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized phase II study. Breast Cancer Res Treat 133:237\u2013246. https:\/\/doi.org\/10.1007\/s10549-011-1947-7","journal-title":"Breast Cancer Res Treat"},{"key":"2648_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40487-017-0046-2","volume":"5","author":"MR Nathan","year":"2017","unstructured":"Nathan MR, Schmid P (2017) A review of fulvestrant in breast cancer. Oncol Ther 5:17\u201329. https:\/\/doi.org\/10.1007\/s40487-017-0046-2","journal-title":"Oncol Ther"},{"key":"2648_CR16","doi-asserted-by":"publisher","first-page":"R18","DOI":"10.1186\/bcr3393","volume":"15","author":"JF Robertson","year":"2013","unstructured":"Robertson JF, Dixon JM, Sibbering DM et al (2013) A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. Breast Cancer Res 15:R18. https:\/\/doi.org\/10.1186\/bcr3393","journal-title":"Breast Cancer Res"},{"key":"2648_CR17","unstructured":"Orserdu: elacestrant. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/orserdu. Updated September 10, 2023. Accessed 16 Apr 2024"},{"key":"2648_CR18","unstructured":"Orserdu: elacestrant dihydroclhoride. US Food & Drug Administration. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=217639. Updated January 27, 2023. Accessed 16 Apr 2024"},{"key":"2648_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2019.110452","volume":"493","author":"JJ Flanagan","year":"2019","unstructured":"Flanagan JJ, Neklesa TK (2019) Targeting nuclear receptors with PROTAC degraders. Mol Cell Endocrinol 493:110452. https:\/\/doi.org\/10.1016\/j.mce.2019.110452","journal-title":"Mol Cell Endocrinol"},{"key":"2648_CR20","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS18-P5-04-18","author":"J Flanagan","year":"2018","unstructured":"Flanagan J, Qian Y, Gough S et al (2018) ARV-471, an oral estrogen receptor PROTAC\u2122 protein degrader for breast cancer. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS18-P5-04-18","journal-title":"Cancer Res"},{"key":"2648_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21:181\u2013200. https:\/\/doi.org\/10.1038\/s41573-021-00371-6","journal-title":"Nat Rev Drug Discov"},{"key":"2648_CR22","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"S Gough","year":"2024","unstructured":"Gough S, Flanagan J, Teh J et al (2024) Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models. Clin Cancer Res 30:3549\u20133563. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3465","journal-title":"Clin Cancer Res"},{"key":"2648_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.567","author":"E Hamilton","year":"2023","unstructured":"Hamilton E, Han H, Schott A et al (2023) Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader, in estrogen receptor+\/human epidermal growth factor receptor 2- advanced breast cancer: update of dose escalation results from a phase 1\/2 trial. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.567","journal-title":"Ann Oncol"},{"key":"2648_CR24","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS23-PO3-05-08","author":"S Hurvitz","year":"2024","unstructured":"Hurvitz S, Schott A, Ma C et al (2024) Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER\u2013positive\/human epidermal growth factor receptor 2 (HER2)\u2013negative advanced breast cancer. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS23-PO3-05-08","journal-title":"Cancer Res"},{"key":"2648_CR25","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-GS3-03","author":"S Hurvitz","year":"2023","unstructured":"Hurvitz S, Schott A, Ma C et al (2023) ARV-471, a PROTAC\u00ae estrogen receptor (ER) degrader in advanced ER-positive\/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1\/2 study.  Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-GS3-03","journal-title":"Cancer Res"},{"key":"2648_CR26","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.20517\/cdr.2019.66","volume":"2","author":"C Lo Nigro","year":"2019","unstructured":"Lo Nigro C, Rusmini M, Ceccherini I (2019) RET in breast cancer: pathogenic implications and mechanisms of drug resistance. Cancer Drug Resist 2:1136\u20131152. https:\/\/doi.org\/10.20517\/cdr.2019.66","journal-title":"Cancer Drug Resist"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02648-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T13:02:48Z","timestamp":1735995768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02648-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2648"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02648-3","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H Iwata has received honoraria and research funding from Pfizer. Y Naito has received honoraria and\/or other fees for conference attendance from Chugai, Daiichi Sankyo, and Eli Lilly; received research funds from AbbVie, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Eisai, Pfizer, Taiho, and Takeda. M Hattori has received honoraria from Daiichi Sankyo, MSD, and Eli Lilly; received research funding from Konica Minolta. A Yoshimura has nothing to disclose. K Yonemori has received honoraria from Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR pharma, MSD, Boehringer Ingelheim, Ono, Daiichi Sankyo, Bayer, Jansen, Asteras, Bristol Myers Squibb, Novartis, Sanofi, and Merk Biopharma; received research support (to institution) from MSD, Daiichi Sankyo, Merk Biopharma, AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle Genetics, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe. M Aizawa is an employee of Pfizer R&D Japan. Y Mori is an employee of Pfizer R&D Japan and holds stock in Pfizer Inc. J Yoshimitsu is an employee of Pfizer R&D Japan. Y Umeyama is an employee of Pfizer R&D Japan and holds stock in Pfizer Inc. T Mukohara has received honoraria from Daiichi Sankyo, Eli Lilly, Eisai, Pfizer, Novartis, Chugai, AstraZeneca, Kyowa Kirin, and Taiho; received research funds from AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Gilead Sciences, MSD, Novartis, Ono, Pfizer, Sanofi, and Sysmex. Role of the sponsor: The funders had a role in the design and conduct of the study; data collection, management, and analysis of the data. The drafting of the manuscript, review, and decision to submit for publication were made by all the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval of the study protocol by an Institutional Reviewer Board: The protocol, ICF, Investigator Brochure, and other relevant documents were submitted to an IRB\/EC by the investigator and reviewed and approved by the IRB\/EC before the study was initiated. These IRBs include the following: IRB at Aichi Cancer Center Hospital, IRB at National Cancer Center Hospital East, and IRB at National Cancer Center Hospital. This study was conducted in accordance with the protocol and consensus ethical principles derived from international guidelines, including the Declaration of Helsinki Council and CIOMS International Ethical Guidelines, applicable ICH GCP Guidelines, applicable ISO 14155 guidelines, medical device guidelines, and other applicable laws and regulations, including privacy laws.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided written informed consent prior to the study. Registry and the Registration no. of the study\/trial: This study is registered on ClinicalTrials.gov (NCT05463952).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}]}}